参松养心胶囊联合西药治疗阵发性房颤疗效和安全性的Meta分析

发布时间：2018-11-19 13:02

【摘要】：目的:对参松养心胶囊联合西药治疗阵发性房颤的疗效和安全性进行系统性评价。方法:以主题词结合自由词相结合、计算机检索结合手工检索相结合的检索方法,检索中国知网(CNKI)、万方数据资源系统(WANFANG DATA)、中文科技期刊数据库(VIP)、Pub Med、Embase、Cochrane及其他中医药相关期刊中相关的文献;严格按照纳入标准筛选文献,并根据Jadad量表的质量标准和Cochrane协作网偏倚风险评估工具对纳入文献的质量进行评价;提取文献中的原始数据;运用Rev Man 5.3软件对数据进行分析,客观评价其疗效。结果:试验组治疗效果优于对照组[OR=3.66,95%IC(2.66,5.02)];治疗后试验组房颤发生频率低于对照组[MD=-4.17,95%IC(-5.71,-2.63)];治疗后试验组左房内径小于对照组[MD=-1.44,95%IC(-1.95,-0.93)];治疗后试验组p波离散度小于对照组[MD=-7.33,95%IC(-10.21,-4.44)];治疗后试验组6 min步行试验改善程度优于对照组[MD=58.98,95%IC(43.13,74.84)]。参松养心胶囊联合西药治疗阵发性房颤的不良反应少,安全性好。结论:参松养心胶囊联合西药治疗阵发性房颤的疗效优于单纯西药治疗,且安全性好,值得临床推广。但本研究纳入文献总体质量不高,且发表偏倚可能存在,所以仍需更多高质量随机双盲对照临床试验进一步验证。
[Abstract]:Objective: to evaluate the efficacy and safety of Shensong Yangxin capsule combined with western medicine in the treatment of paroxysmal atrial fibrillation. Methods: with the combination of subject words and free words, computer retrieval combined with manual retrieval, the Chinese scientific and technological periodical database (VIP), Pub Med,Embase, of (CNKI), Wanfang data resource system of China Zhiwang was searched. Related literature in Cochrane and other journals related to traditional Chinese medicine; According to the quality standard of Jadad scale and the risk assessment tool of Cochrane cooperative network bias, the quality of the included documents was evaluated, and the original data of the literature were extracted. Rev Man 5.3 software was used to analyze the data and evaluate the curative effect objectively. Results: the treatment effect of the trial group was better than that of the control group [OR=3.66,95%IC (2.66 卤5.02)], the frequency of atrial fibrillation in the experimental group was lower than that in the control group [MD=-4.17,95%IC (-5.71 卤2.63)]. After treatment, the left atrial diameter in the experimental group was smaller than that in the control group [MD=-1.44,95%IC (-1.95 卤0.93)], the P-wave dispersion in the experimental group was smaller than that in the control group [MD=-7.33,95%IC (-10.21 卤4.44)]. After treatment, the improvement of 6 min walking test in the trial group was better than that in the control group [MD=58.98,95%IC (43.13 ~ 74.84)]. Shensong Yangxin capsule combined with western medicine in the treatment of paroxysmal atrial fibrillation has few adverse reactions and good safety. Conclusion: the efficacy of Shensong Yangxin capsule combined with western medicine in treating paroxysmal atrial fibrillation is better than that of western medicine alone, and it is safe and worthy of clinical popularization. However, the overall quality of this study is not high, and publication bias may exist, so more high quality randomized double-blind controlled clinical trials are needed.
【作者单位】：广西中医药大学研究生院;广西中医药大学附属瑞康医院;
【基金】：国家自然科学基金项目(81360535) 广西科学研究与技术开发计划项目(桂科攻1598012-55)
【分类号】：R541.75

【相似文献】